The Current Place of Tranexamic Acid in the Elective Hip Arthroplasty
| Autoři | |
|---|---|
| Rok publikování | 2022 |
| Druh | Článek ve sborníku |
| Konference | Noninvasive methods in cardiology 2022 |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://is.muni.cz/do/med/noninvasive_methods_in_cardiology/Noninvasive_methods_in_cardiology_2022.pdf |
| Klíčová slova | Elective Hip Arthroplasty; Tranexamic Acid |
| Popis | The total hip arthroplasties (???) are associated with perioperative blood losses exceeding 500 mL, some studies claim average blood losses of up to 1500Ml [1]. Blood loss volumes are certainly strongly dependent on the chosen surgical approach and technique. Approximately 30% of patients that undergo elective hip replacement receive at least one blood unit in postoperative care [2]. Reducing blood losses has a beneficial impact on recovery time, length of stay, and health economics. In the last decade, there has been an increasing interest in the efficacy of tranexamic acid (TXA) in orthopaedics and especially in elective major joint replacements. Highlighted advantages of the TXA in hip replacement surgery are the systemic or local prevention of hemorrhage and the prevention of heterotopic ossification formation. This paper presents an overview of our current understanding of the use of TXA in elective hip replacement. |